CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics
Authors
Keywords
Alzheimer’s disease, Neurodegeneration, CRISPR/Cas9, Gene editing, Therapeutics, Presenilin, APP
Journal
Journal of Advanced Research
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-07-06
DOI
10.1016/j.jare.2021.07.001
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors
- (2020) Dan Wang et al. CELL
- CRISPR/Cas9 novel therapeutic road for the treatment of neurodegenerative diseases
- (2020) Ansar Karimian et al. LIFE SCIENCES
- Science Runs and the Debate Brakes: Somatic Gene-Editing as a New Tool for Gender-Specific Medicine in Alzheimer’s Disease
- (2020) Pamela Tozzo et al. Brain Sciences
- Alzheimer's disease-like perturbations in HIV-mediated neuronal dysfunctions: understanding mechanisms and developing therapeutic strategies
- (2020) Niraj Kumar Jha et al. Open Biology
- Mechanistic Interplay between Autophagy and Apoptotic Signaling in Endosulfan-induced Dopaminergic Neurotoxicity: Relevance to the Adverse Outcome Pathway in Pesticide Neurotoxicity
- (2019) Chunjuan Song et al. TOXICOLOGICAL SCIENCES
- GSAP modulates γ-secretase specificity by inducing conformational change in PS1
- (2019) Eitan Wong et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- In vivo neuronal gene editing via CRISPR–Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer’s disease
- (2019) Hanseul Park et al. NATURE NEUROSCIENCE
- Nuclear factor‐kappa β as a therapeutic target for Alzheimer's disease
- (2019) Niraj Kumar Jha et al. JOURNAL OF NEUROCHEMISTRY
- Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in alzheimer disease
- (2019) Anil R. Wadhwani et al. ANNALS OF NEUROLOGY
- ABC transporters in neurological disorders: an important gateway for botanical compounds mediated neuro-therapeutics
- (2019) Niraj Kumar Jha et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Advancements in CRISPR/Cas9 technology—Focusing on cancer therapeutics and beyond
- (2019) Zeenat Mirza et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Search-and-replace genome editing without double-strand breaks or donor DNA
- (2019) Andrew V. Anzalone et al. NATURE
- Towards gene-editing treatment for alzheimer's disease: ApoE4 allele-specific knockout using a CRISPR cas9 variant
- (2018) D. Offen et al. CYTOTHERAPY
- Hypoxia-Induced Signaling Activation in Neurodegenerative Diseases: Targets for New Therapeutic Strategies
- (2018) Niraj Kumar Jha et al. JOURNAL OF ALZHEIMERS DISEASE
- Generation of a New Tau Knockout (tauΔex1) Line Using CRISPR/Cas9 Genome Editing in Mice
- (2018) Daniel C.S. Tan et al. JOURNAL OF ALZHEIMERS DISEASE
- Targeted Gene Editing of Glia Maturation Factor in Microglia: a Novel Alzheimer’s Disease Therapeutic Target
- (2018) Sudhanshu P. Raikwar et al. MOLECULAR NEUROBIOLOGY
- iPSC-derived familial Alzheimer’s PSEN2 N141I cholinergic neurons exhibit mutation-dependent molecular pathology corrected by insulin signaling
- (2018) Cesar L. Moreno et al. Molecular Neurodegeneration
- Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector
- (2018) Chengzhong Wang et al. NATURE MEDICINE
- Generation of App knock-in mice reveals deletion mutations protective against Alzheimer’s disease-like pathology
- (2018) Kenichi Nagata et al. Nature Communications
- Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility
- (2018) Jayesh A. Kulkarni et al. Nucleic Acid Therapeutics
- CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer’s Disease
- (2018) Bence György et al. Molecular Therapy-Nucleic Acids
- Tau Phosphorylation, Molecular Chaperones, and Ubiquitin E3 Ligase: Clinical Relevance in Alzheimer's Disease
- (2018) Pravir Kumar et al. JOURNAL OF ALZHEIMERS DISEASE
- Downregulation of SNCA Expression by Targeted Editing of DNA Methylation: A Potential Strategy for Precision Therapy in PD
- (2018) Boris Kantor et al. MOLECULAR THERAPY
- Engineering synucleinopathy-resistant human dopaminergic neurons by CRISPR-mediated deletion of the SNCA gene
- (2018) Yixi Chen et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- CRISPR/Cas9 editing of APP C-terminus attenuates β-cleavage and promotes α-cleavage
- (2018) Jichao Sun et al. Nature Communications
- CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington’s Disease
- (2017) Nivya Kolli et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Stress-Induced Synaptic Dysfunction and Neurotransmitter Release in Alzheimer’s Disease: Can Neurotransmitters and Neuromodulators be Potential Therapeutic Targets?
- (2017) Saurabh Kumar Jha et al. JOURNAL OF ALZHEIMERS DISEASE
- CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease
- (2017) Su Yang et al. JOURNAL OF CLINICAL INVESTIGATION
- Microtubule dynamics and the neurodegenerative triad of Alzheimer's disease: The hidden connection
- (2017) Roland Brandt et al. JOURNAL OF NEUROCHEMISTRY
- CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo
- (2017) Alex Mas Monteys et al. MOLECULAR THERAPY
- Genome-wide CRISPR screen for PARKIN regulators reveals transcriptional repression as a determinant of mitophagy
- (2017) Christoph Potting et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CRISPR/Cas9 and piggyBac-mediated footprint-free LRRK2-G2019S knock-in reveals neuronal complexity phenotypes and α-Synuclein modulation in dopaminergic neurons
- (2017) Xiaobing Qing et al. Stem Cell Research
- FACS-Assisted CRISPR-Cas9 Genome Editing Facilitates Parkinson's Disease Modeling
- (2017) Jonathan Arias-Fuenzalida et al. Stem Cell Reports
- CRISPR-Cas Genome Surgery in Ophthalmology
- (2017) James E. DiCarlo et al. Translational Vision Science & Technology
- CRISPR/Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer’s PSEN2 N141I neurons
- (2017) Maitane Ortiz-Virumbrales et al. Acta Neuropathologica Communications
- Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9
- (2016) Jun Wan Shin et al. HUMAN MOLECULAR GENETICS
- Genome Engineering Using Adeno-associated Virus: Basic and Clinical Research Applications
- (2016) Thomas Gaj et al. MOLECULAR THERAPY
- Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9
- (2016) Dominik Paquet et al. NATURE
- Parkinson-associated risk variant in distal enhancer of α-synuclein modulates target gene expression
- (2016) Frank Soldner et al. NATURE
- Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
- (2016) Alexis C. Komor et al. NATURE
- Generation of a gene-corrected isogenic control hiPSC line derived from a familial Alzheimer's disease patient carrying a L150P mutation in presenilin 1
- (2016) Anna Poon et al. Stem Cell Research
- Generation of a gene-corrected isogenic control cell line from an Alzheimer's disease patient iPSC line carrying a A79V mutation in PSEN1
- (2016) Carlota Pires et al. Stem Cell Research
- Prokineticin-2 upregulation during neuronal injury mediates a compensatory protective response against dopaminergic neuronal degeneration
- (2016) Richard Gordon et al. Nature Communications
- One-step generation of triple gene-targeted pigs using CRISPR/Cas9 system
- (2016) Xianlong Wang et al. Scientific Reports
- CRISPR/Cas9: Implications for Modeling and Therapy of Neurodegenerative Diseases
- (2016) Weili Yang et al. Frontiers in Molecular Neuroscience
- Alzheimer’s disease-associated mutations increase amyloid precursor protein resistance to γ-secretase cleavage and the Aβ42/Aβ40 ratio
- (2016) Ting-Hai Xu et al. Cell Discovery
- Self-Assembled DNA Nanoclews for the Efficient Delivery of CRISPR-Cas9 for Genome Editing
- (2015) Wujin Sun et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Low Incidence of Off-Target Mutations in Individual CRISPR-Cas9 and TALEN Targeted Human Stem Cell Clones Detected by Whole-Genome Sequencing
- (2014) Adrian Veres et al. Cell Stem Cell
- Generation of CRISPR/Cas9-mediated gene-targeted pigs via somatic cell nuclear transfer
- (2014) Xiaoqing Zhou et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9
- (2014) Rajat M. Gupta et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting the β secretase BACE1 for Alzheimer's disease therapy
- (2014) Riqiang Yan et al. LANCET NEUROLOGY
- ApoE and Aβ in Alzheimer’s Disease: Accidental Encounters or Partners?
- (2014) Takahisa Kanekiyo et al. NEURON
- Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
- (2014) Jeffrey L Cummings et al. Alzheimers Research & Therapy
- Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity
- (2013) F. Ann Ran et al. CELL
- Glia Maturation Factor Induces Interleukin-33 Release from Astrocytes: Implications for Neurodegenerative Diseases
- (2013) Duraisamy Kempuraj et al. Journal of Neuroimmune Pharmacology
- Activity-Induced Convergence of APP and BACE-1 in Acidic Microdomains via an Endocytosis-Dependent Pathway
- (2013) Utpal Das et al. NEURON
- Genetic insights in Alzheimer's disease
- (2012) Karolien Bettens et al. LANCET NEUROLOGY
- A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity
- (2012) M. Jinek et al. SCIENCE
- AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial
- (2011) Peter A LeWitt et al. LANCET NEUROLOGY
- Targeted Delivery of Cargoes into a Murine Solid Tumor by a Cell-Penetrating Peptide and Cleavable Poly(ethylene glycol) Comodified Liposomal Delivery System via Systemic Administration
- (2011) Rui Kuai et al. MOLECULAR PHARMACEUTICS
- Genetics: Finding risk factors
- (2011) Michael Eisenstein NATURE
- APP processing in Alzheimer's disease
- (2011) Yun-wu Zhang et al. Molecular Brain
- Disease-modifying treatments for Alzheimer’s disease
- (2011) Daniela Galimberti et al. Therapeutic Advances in Neurological Disorders
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search